Key Considerations and Strategies for Strengthening Covid-19 Diagnostics Supply Chains in Low-Middle Income Country Settings
The demand for Covid-19 diagnostics has exploded with the global impact of the pandemic, though this demand for diagnostics, reagents, and consumables for Covid-19 is causing shortages of commodities worldwide. These challenges have considerable impact on low- and middle-income countries which are significantly resource constrained and lack the political clout or relative buying power to secure supplies.
So how do countries make evidence-based choices for selection of products available? How do countries secure supply while mitigating the risks related to quality assurance? How do countries build resilient supply chains that can address these issues?
This guidance document outlines the major challenges and potential mitigation strategies to support Low- and Middle-Income Countries in securing access to appropriate, quality assured, and adequate Covid-19 diagnostics.
DISCLAIMER:
Due the dynamic nature of diagnostics market, this documentation and information will be updated periodically.
MSH and The Rockefeller Foundation do not guarantee the accuracy, completeness or integrity of the information collected from the secondary data sources and interviewees. Further, the information is provided for informational purposes only and is not intended as an endorsement, guidance, recommendations, or advice for any particular product, program or policy. Any use or interpretation of or reliance on the information for any purpose, is solely and exclusively the responsibility of the recipients of the information. THE INFORMATION IS PROVIDED “AS IS”. NO WARRANTY OF ANY KIND IS GIVEN FOR THE INFORMATION UNDER ANY NATIONAL OR INTERNATIONAL LAW, INCLUDING WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY. MSH AND THE ROCKEFELLER FOUNDATION expressly disclaim and assume no responsibility for any losses, damages, claims, or other liabilities, including loss of good will, revenue, profits, or business interruption, or any consequential, special, indirect, incidental, punitive or exemplary loss, including costs of defense or attorneys’ fees, arising out of or relating to use of this information. It is expressly understood that the MSH and The Rockefeller Foundation, by providing this information, have no obligation to update the information or provide additional support or information to the recipient.